Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Todd L. Astor"'
Autor:
Todd L. Astor, Hilary J. Goldberg, Laurie D. Snyder, Andrew Courtwright, Ramsey Hachem, Tahuanty Pena, Lorenzo Zaffiri, Gerard J. Criner, Marie M. Budev, Tany Thaniyavarn, Thomas B. Leonard, Shaun Bender, Aliaa Barakat, Janis L. Breeze, Peter LaCamera
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 17 (2023)
Background: It is unclear whether continuing anti-fibrotic therapy until the time of lung transplant increases the risk of complications in patients with idiopathic pulmonary fibrosis. Objectives: To investigate whether the time between discontinuati
Externí odkaz:
https://doaj.org/article/166e744374eb43c283b130537cffc784
Autor:
Jocelyn R. Farmer, Caroline L. Sokol, Francisco A. Bonilla, Mandakolathur R. Murali, Richard L. Kradin, Todd L. Astor, Jolan E. Walter
Publikováno v:
Case Reports in Immunology, Vol 2014 (2014)
Humoral immune deficiencies have been associated with noninfectious disease complications including autoimmune cytopenias and pulmonary disease. Herein we present a patient who underwent splenectomy for autoimmune cytopenias and subsequently was diag
Externí odkaz:
https://doaj.org/article/9c15c1f64b6547ed8b7bb80cc94066d5
Autor:
Todd L. Astor, Jeffrey T. Borenstein
Publikováno v:
Artificial Organs. 46:1227-1239
The increasing prevalence of chronic lung disease worldwide, combined with the emergence of multiple pandemics arising from respiratory viruses over the past century, highlights the need for safer and efficacious means for providing artificial lung s
Autor:
Todd L. Astor, Masaki Funamoto, Navyatha Mohan, Mauricio A. Villavicencio, Chin Siang Ong, Thoralf M. Sundt, Serguei Melnitchouk, Asishana A. Osho, Selena S. Li, Philicia Moonsamy
Publikováno v:
The Annals of Thoracic Surgery. 112:1797-1804
Background Historically, a glomerular filtration rate (GFR) of less than 50 mL/min per 1.73 m2 has been considered a contraindication to lung transplantation. Combined or sequential lung–kidney transplantation is an option for those with a GFR less
Autor:
Alessandra Tebaldi, Clemens Aigner, Víctor Monforte, Ilhan Inci, James C. Lee, Steven D. Nathan, Rade Tomic, V. Boussaud, Elena Seminari, Chadi A. Hage, Marc G. Schecter, Todd L. Astor, S. Chandrashekaran, Mark Greer, Robin Vos, Julia Klesney-Tait, Ramsey R. Hachem, Astrid Smud, Eloi Prud'Homme, Romain Kessler, C. Saint-Raymond, Jonathan P. Singer, Paganelli Gm, Greg Snell, Erik A M Verschuuren, John-David Aubert, Sami Hraiech, Keith M. Wille, Jas Zarmar, Adrien Tissot, Ma Piedad Ussetti, Anne Marie Rabain, Peter Jaksch, Amy E. Hackmann, Anna Nolde, Kevin Carney, Gerdt Riise, Martin R. Zamora, Christoph Krapf, Edward R. Garrity, Christiane Knoop, Hakim Azfar Ali, David Bennett, Jan Havlin, Lianne G. Singer, Aurélie Le Borgne, Philippe Montravers, Jose Manuel Vaquero, Ivan M. Robbins, Aldo Manuel Álvarez Moran, Are Martin Holm, Kevin M. Chan, Tanya McWilliams, Martine Reynaud-Gaubert, Alan Betensley, Benjamin Renaud-Picard, Charles Poirier, Takuro Miyazaki, Tanel Laisaar, Ichiro Yoshino, Pascal Thomas, Robert M. Reed, Nadim Cassir, Monica Loy, Marc Leone, Daniel C. Chambers, Jeremy A. Falk, Lorenzo Rosso, Julie Samuel, Hillevi Larsson, Karen Doucette, Bartosz Kubisa, Patrick Evrard, Benjamin Coiffard, Gordon L. Yung, Sarah Kilbourne, Michael Perch, Juan Manuel Osses, David van Duin, Philipp M. Lepper, Federico Venuta, Elodie Blanchard, André Nathan Costa, Reda E. Girgis, Reinaldo Rampolla, Masayuki Chida, Richard D. Cornwell, Jérôme Le Pavec, Amit D. Parulekar, Moo Suk Park, Alessandro Bertani, Yoram A. Puius, Jose Cifrian, Robert D. Levy, Antoine Roux, Yoshinori Okada, Takeshi Shiraishi, Marie Budev, Toyofumi F. Chen-Yoshikawa, Paola Soccal, Cynthia Gries, Cassie C. Kennedy, Daniel F. Dilling, Laurent Papazian, Luca Paoletti, Johanna M. Kwakkel-van Erp, Allan R. Glanville, Federica Meloni
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, BioMed Central, 2020, 20 (1), ⟨10.1186/s12890-020-1151-9⟩
BMC pulmonary medicine, Vol. 20, no. 1, p. 109 (2020)
BMC Pulmonary Medicine, 2020, 20 (1), ⟨10.1186/s12890-020-1151-9⟩
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Pulmonary Medicine, BioMed Central, 2020, 20 (1), ⟨10.1186/s12890-020-1151-9⟩
BMC pulmonary medicine, Vol. 20, no. 1, p. 109 (2020)
BMC Pulmonary Medicine, 2020, 20 (1), ⟨10.1186/s12890-020-1151-9⟩
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-9 (2020)
Background Infection is the most common cause of mortality within the first year after lung transplantation (LTx). The management of perioperative antibiotic therapy is a major issue, but little is known about worldwide practices. Methods We sent by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33477c830014bb96fad05be0e71ddfad
https://hal-amu.archives-ouvertes.fr/hal-02564182
https://hal-amu.archives-ouvertes.fr/hal-02564182
Autor:
Todd L. Astor, T. Pena, Laurie D. Snyder, Gerard J. Criner, Shaun Bender, J. Breeze, Ramsey R. Hachem, Lorenzo Zaffiri, Howard M. Lazarus, A. Barakat, T. Thaniyavarn, A. Courtwright, Marie Budev, Hilary J. Goldberg, P. LaCamera
Publikováno v:
B23. LUNG TRANSPLANTATION II.
Autor:
Todd L. Astor, J. Palafox, L. Irwin, O. Delgado, C. McEnery, D. Basler, Mauricio A. Villavicencio
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S483-S484
Purpose Over the past several years 37 to 41% of all deceased donor organs in Region 1 were designated as Public Health Service increased risk for infectious disease transmission compared to 25-27% nationally. Limited by the number of standard donors
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S376
Purpose Calcineurin inhibitor (CNI) or mammalian target of rapamycin inhibitor (mTORi) maintenance immunosuppression (MI) may lead to complications that require interim alternative therapies. The goal of this study was to evaluate the safety and effi
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S343
Purpose Cytomegalovirus Intravenous Immune Globulin (CMV-IVIG) is approved for prophylaxis of CMV disease after transplant due to its ability to provide antibodies against cytomegalovirus. The use of CMV-IVIG has been restricted at many transplant ce
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S485
Purpose Cytomegalovirus (CMV) remains a significant cause of acute morbidity following lung transplantation, and has been linked to the early onset of chronic allograft rejection. Most lung transplant centers utilize prophylaxis with valganciclovir (